Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31


Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-Mutant Lung Cancer.

Dagogo-Jack I, Martinez P, Yeap BY, Ambrogio C, Ferris LA, Lydon C, Nguyen T, Jessop NA, Iafrate AJ, Johnson BE, Lennerz JK, Shaw AT, Awad MM.

Clin Cancer Res. 2018 Sep 17. pii: clincanres.2062.2018. doi: 10.1158/1078-0432.CCR-18-2062. [Epub ahead of print]


Targeting oncogenic drivers in lung cancer: Recent progress, current challenges and future opportunities.

Yoda S, Dagogo-Jack I, Hata AN.

Pharmacol Ther. 2018 Aug 16. pii: S0163-7258(18)30145-1. doi: 10.1016/j.pharmthera.2018.08.007. [Epub ahead of print] Review.


Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer.

Chaft JE, Dagogo-Jack I, Santini FC, Eng J, Yeap BY, Izar B, Chin E, Jones DR, Kris MG, Shaw AT, Gainor JF.

Lung Cancer. 2018 Aug;122:67-71. doi: 10.1016/j.lungcan.2018.05.020. Epub 2018 May 22.


Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC.

Lin JJ, Zhu VW, Schoenfeld AJ, Yeap BY, Saxena A, Ferris LA, Dagogo-Jack I, Farago AF, Taber A, Traynor A, Menon S, Gainor JF, Lennerz JK, Plodkowski AJ, Digumarthy SR, Ou SI, Shaw AT, Riely GJ.

J Thorac Oncol. 2018 Oct;13(10):1530-1538. doi: 10.1016/j.jtho.2018.06.005. Epub 2018 Jun 20.


Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer.

Yoda S, Lin JJ, Lawrence MS, Burke BJ, Friboulet L, Langenbucher A, Dardaei L, Prutisto-Chang K, Dagogo-Jack I, Timofeevski S, Hubbeling H, Gainor JF, Ferris LA, Riley AK, Kattermann KE, Timonina D, Heist RS, Iafrate AJ, Benes CH, Lennerz JK, Mino-Kenudson M, Engelman JA, Johnson TW, Hata AN, Shaw AT.

Cancer Discov. 2018 Jun;8(6):714-729. doi: 10.1158/2159-8290.CD-17-1256. Epub 2018 Apr 12.


SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors.

Dardaei L, Wang HQ, Singh M, Fordjour P, Shaw KX, Yoda S, Kerr G, Yu K, Liang J, Cao Y, Chen Y, Lawrence MS, Langenbucher A, Gainor JF, Friboulet L, Dagogo-Jack I, Myers DT, Labrot E, Ruddy D, Parks M, Lee D, DiCecca RH, Moody S, Hao H, Mohseni M, LaMarche M, Williams J, Hoffmaster K, Caponigro G, Shaw AT, Hata AN, Benes CH, Li F, Engelman JA.

Nat Med. 2018 May;24(4):512-517. doi: 10.1038/nm.4497. Epub 2018 Mar 5.


Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNA.

Dagogo-Jack I, Brannon AR, Ferris LA, Campbell CD, Lin JJ, Schultz KR, Ackil J, Stevens S, Dardaei L, Yoda S, Hubbeling H, Digumarthy SR, Riester M, Hata AN, Sequist LV, Lennes IT, Iafrate AJ, Heist RS, Azzoli CG, Farago AF, Engelman JA, Lennerz JK, Benes CH, Leary RJ, Shaw AT, Gainor JF.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00160. Epub 2018 Jan 23.


Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer.

Lin JJ, Zhu VW, Yoda S, Yeap BY, Schrock AB, Dagogo-Jack I, Jessop NA, Jiang GY, Le LP, Gowen K, Stephens PJ, Ross JS, Ali SM, Miller VA, Johnson ML, Lovly CM, Hata AN, Gainor JF, Iafrate AJ, Shaw AT, Ou SI.

J Clin Oncol. 2018 Apr 20;36(12):1199-1206. doi: 10.1200/JCO.2017.76.2294. Epub 2018 Jan 26.


Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non-Small-Cell Lung Cancer.

Gainor JF, Tseng D, Yoda S, Dagogo-Jack I, Friboulet L, Lin JJ, Hubbeling HG, Dardaei L, Farago AF, Schultz KR, Ferris LA, Piotrowska Z, Hardwick J, Huang D, Mino-Kenudson M, Iafrate AJ, Hata AN, Yeap BY, Shaw AT.

JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.17.00063. Epub 2017 Aug 16.


Tumour heterogeneity and resistance to cancer therapies.

Dagogo-Jack I, Shaw AT.

Nat Rev Clin Oncol. 2018 Feb;15(2):81-94. doi: 10.1038/nrclinonc.2017.166. Epub 2017 Nov 8. Review.


Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patients.

Ou SI, Horn L, Cruz M, Vafai D, Lovly CM, Spradlin A, Williamson MJ, Dagogo-Jack I, Johnson A, Miller VA, Gadgeel S, Ali SM, Schrock AB.

Lung Cancer. 2017 Sep;111:61-64. doi: 10.1016/j.lungcan.2017.07.006. Epub 2017 Jul 11.


Brain Metastasis: Clinical Implications of Branched Evolution.

Dagogo-Jack I, Carter SL, Brastianos PK.

Trends Cancer. 2016 Jul;2(7):332-337. doi: 10.1016/j.trecan.2016.06.005. Epub 2016 Jun 29. Review.


The Role of Liquid Biopsies in Lung Cancer Screening.

Dagogo-Jack I, Sequist LV, Piotrowska Z.

Semin Roentgenol. 2017 Jul;52(3):185-187. doi: 10.1053/ Epub 2017 Jun 3. No abstract available.


Pathology Issues in Thoracic Oncology: Histologic Characterization and Tissue/Plasma Genotyping May Resolve Diagnostic Dilemmas.

Dagogo-Jack I, Saltos A, Shaw AT, Gray JE.

Am Soc Clin Oncol Educ Book. 2017;37:619-629. doi: 10.14694/EDBK_175197. Review.


Expanding the Roster of ROS1 Inhibitors.

Dagogo-Jack I, Shaw AT.

J Clin Oncol. 2017 Aug 10;35(23):2595-2597. doi: 10.1200/JCO.2017.73.2586. Epub 2017 May 18. No abstract available.


Circulating Tumor DNA Identifies EGFR Coamplification as a Mechanism of Resistance to Crizotinib in a Patient with Advanced MET-Amplified Lung Adenocarcinoma.

Dagogo-Jack I, Fabrizio D, Lennerz J, Schrock AB, Young L, Mino-Kenudson M, Digumarthy SR, Heist RS, Ali SM, Miller VA, Shaw AT.

J Thorac Oncol. 2017 Oct;12(10):e155-e157. doi: 10.1016/j.jtho.2017.04.023. Epub 2017 May 9. No abstract available.


A Retrospective Analysis of the Efficacy of Pembrolizumab in Melanoma Patients With Brain Metastasis.

Dagogo-Jack I, Lanfranchi M, Gainor JF, Giobbie-Hurder A, Lawrence DP, Shaw AT, Sullivan RJ.

J Immunother. 2017 Apr;40(3):108-113. doi: 10.1097/CJI.0000000000000159.


Optimizing treatment for patients with anaplastic lymphoma kinase-positive lung cancer.

Dagogo-Jack I, Shaw AT, Riely GJ.

Clin Pharmacol Ther. 2017 May;101(5):625-633. doi: 10.1002/cpt.653. Epub 2017 Mar 17. Review.


Treatment of brain metastases in the modern genomic era.

Dagogo-Jack I, Gill CM, Cahill DP, Santagata S, Brastianos PK.

Pharmacol Ther. 2017 Feb;170:64-72. doi: 10.1016/j.pharmthera.2016.10.011. Epub 2016 Oct 20. Review.


Crizotinib resistance: implications for therapeutic strategies.

Dagogo-Jack I, Shaw AT.

Ann Oncol. 2016 Sep;27 Suppl 3:iii42-iii50. doi: 10.1093/annonc/mdw305. Review.


Use and Yield of Baseline Imaging and Laboratory Testing in Stage II Breast Cancer.

Bychkovsky BL, Guo H, Sutton J, Spring L, Faig J, Dagogo-Jack I, Battelli C, Houlihan MJ, Yeh TC, Come SE, Lin NU.

Oncologist. 2016 Dec;21(12):1495-1501. Epub 2016 Aug 22.


Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.

Gainor JF, Dardaei L, Yoda S, Friboulet L, Leshchiner I, Katayama R, Dagogo-Jack I, Gadgeel S, Schultz K, Singh M, Chin E, Parks M, Lee D, DiCecca RH, Lockerman E, Huynh T, Logan J, Ritterhouse LL, Le LP, Muniappan A, Digumarthy S, Channick C, Keyes C, Getz G, Dias-Santagata D, Heist RS, Lennerz J, Sequist LV, Benes CH, Iafrate AJ, Mino-Kenudson M, Engelman JA, Shaw AT.

Cancer Discov. 2016 Oct;6(10):1118-1133. Epub 2016 Jul 18.


Clinicopathologic Features of NSCLC Diagnosed During Pregnancy or the Peripartum Period in the Era of Molecular Genotyping.

Dagogo-Jack I, Gainor JF, Porter RL, Schultz KR, Solomon BJ, Stevens S, Azzoli CG, Sequist LV, Lennes IT, Shaw AT.

J Thorac Oncol. 2016 Sep;11(9):1522-8. doi: 10.1016/j.jtho.2016.05.031. Epub 2016 Jun 11.


Screening for ALK Rearrangements in Lung Cancer: Time for a New Generation of Diagnostics?

Dagogo-Jack I, Shaw AT.

Oncologist. 2016 Jun;21(6):662-3. doi: 10.1634/theoncologist.2016-0179. Epub 2016 May 31. No abstract available.


Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-Mutant Lung Cancer Harboring De Novo MET Amplification.

Gainor JF, Niederst MJ, Lennerz JK, Dagogo-Jack I, Stevens S, Shaw AT, Sequist LV, Engelman JA.

J Thorac Oncol. 2016 Jul;11(7):e83-5. doi: 10.1016/j.jtho.2016.02.021. Epub 2016 Mar 14. No abstract available.


The utility of routine chest radiography in the initial evaluation of adult patients with febrile neutropenia patients undergoing HSCT.

Yolin-Raley DS, Dagogo-Jack I, Niell HB, Soiffer RJ, Antin JH, Alyea EP 3rd, Glotzbecker BE.

J Natl Compr Canc Netw. 2015 Feb;13(2):184-9.


Interactive medical case. A man with fever, cough, and rash.

Dagogo-Jack I, Vaidya A, Geller B, Baden LR, Stone R.

N Engl J Med. 2014 Aug 21;371(8):e11. doi: 10.1056/NEJMimc1310796. No abstract available.


NOTCH2 and FLT3 gene mis-splicings are common events in patients with acute myeloid leukemia (AML): new potential targets in AML.

Adamia S, Bar-Natan M, Haibe-Kains B, Pilarski PM, Bach C, Pevzner S, Calimeri T, Avet-Loiseau H, Lode L, Verselis S, Fox EA, Galinsky I, Mathews S, Dagogo-Jack I, Wadleigh M, Steensma DP, Motyckova G, Deangelo DJ, Quackenbush J, Tenen DG, Stone RM, Griffin JD.

Blood. 2014 May 1;123(18):2816-25. doi: 10.1182/blood-2013-02-481507. Epub 2014 Feb 26.


A genome-wide aberrant RNA splicing in patients with acute myeloid leukemia identifies novel potential disease markers and therapeutic targets.

Adamia S, Haibe-Kains B, Pilarski PM, Bar-Natan M, Pevzner S, Avet-Loiseau H, Lode L, Verselis S, Fox EA, Burke J, Galinsky I, Dagogo-Jack I, Wadleigh M, Steensma DP, Motyckova G, Deangelo DJ, Quackenbush J, Stone R, Griffin JD.

Clin Cancer Res. 2014 Mar 1;20(5):1135-45. doi: 10.1158/1078-0432.CCR-13-0956. Epub 2013 Nov 27.


Oral cavity tumors in younger patients show a poor prognosis and do not contain viral RNA.

Br├Ągelmann J, Dagogo-Jack I, El Dinali M, Stricker T, Brown CD, Zuo Z, Khattri A, Keck M, McNerney ME, Longnecker R, Bieging K, Kocherginsky M, Alexander K, Salgia R, Lingen MW, Vokes EE, White KP, Cohen EE, Seiwert TY.

Oral Oncol. 2013 Jun;49(6):525-33. doi: 10.1016/j.oraloncology.2013.02.003. Epub 2013 Mar 13.


That which we carry with us.

Dagogo-Jack I.

Pharos Alpha Omega Alpha Honor Med Soc. 2011 Spring;74(2):34-6. No abstract available.


Supplemental Content

Loading ...
Support Center